WithdrawnNCT02929485
Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor
Medication studyAges 18–50United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 50 years.
- Listed locations
- Berkeley and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: July 2013
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- University of California, Berkeley
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT02929485
- Official title
Show the full official title
Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Berkeley · San Francisco
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of California, Berkeley, a university.
Does this study involve medication?
Yes. The study involves medication, including Tolcapone, Placebo and Bromocriptine.
Who can participate?
Listed age limits: 18 years to 50 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
